Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × erdafitinib × Clear all

Phase

Status

Active not recruiting 10 Completed 7 Terminated 4 Recruiting 4 Withdrawn 1 Unknown 1 Not yet recruiting 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Cisplatin 106 Carboplatin 104 Drug Therapy 102 Oxaliplatin 87 Bevacizumab 82 Capecitabine 81 Paclitaxel 77 Cyclophosphamide 75 pembrolizumab 74 Radiotherapy 74 Gemcitabine 73 tislelizumab 70 Specimen Handling 57 toripalimab 55 Fluorouracil 55 Docetaxel 52 Surgical Procedures, Operative 48 Injections 48 sintilimab 47 Magnetic Resonance Spectroscopy 47 130-nm albumin-bound paclitaxel 44 Leucovorin 38 Biopsy 37 anlotinib 36 Pemetrexed 36 fludarabine 35 Standard of Care 35 Immune Checkpoint Inhibitors 35 lenvatinib 34 Radiosurgery 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡